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evaluating balneotherapy in patients with advanced
chronic venous insufﬁciency
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Carole Rolland, MSc,c Christian Roques, MD,d and Jean-Luc Bosson, MD, PhD,c Grenoble, La Léchère, and
Toulouse, France
Background: Apart from compression therapy, physical therapy has scarcely been evaluated in the treatment of chronic
venous disorders (CVDs). Spa treatment is a popular way to administer physical therapy for CVDs in France, but its
efﬁcacy has not yet been assessed in a large trial. The objective was to assess the efﬁcacy of spa therapy for patients with
advanced CVD (CEAP clinical classes C4-C5).
Methods: Thiswas a single-blind (treatment concealed to the investigators) randomized,multicenter, controlled trial (French
spa resorts). Inclusion criteria were primary or post-thrombotic CVD with skin changes but no active ulcer (C4a, C4b, or
C5). The treated group had the usual 3-week spa treatment course soon after randomization; the control group had spa
treatment after the 1-year comparisonperiod.All patients continued their usualmedical care includingwearing compression
stockings. Treatment consisted of four balneotherapy sessions per day for 6 days a week. Follow-up was performed at 6, 12
and 18 months by independent blinded investigators. The main outcome criterion was the incidence of leg ulcers at
12 months. Secondary criteria were a modiﬁed version of the Venous Clinical Severity Score, a visual analog scale for leg
symptoms, and the Chronic Venous Insufﬁciency Questionnaire 2 and EuroQol 5D quality-of-life autoquestionnaires.
Results: Fourhundred twenty-ﬁve subjectswere enrolled: 214 in the treatmentgroup (Spa) and211 in the control group (Ctr);
theywere similar atbaseline regarding theirdemographic characteristics, the severityof theCVD,andtheoutcomevariables.At
1 year, the incidence of leg ulcerswas not statistically different (Spa:D9.3%; 95% conﬁdence interval [CI],D5.6 -D14.3;Ctr:
D6.1%; 95% CI,D3.2 -D10.4), whereas the Venous Clinical Severity Score improved signiﬁcantly in the treatment group
(Spa:L1.2; 95%CI,L1.6 -L0.8; Ctr:L0.6; 95%CI,L1.0 -L0.2;P[ .04). A signiﬁcant difference favoring spa treatment
was found regarding symptoms after 1 year (Spa:L0.03; 95%CI,L0.57 -D0.51; Ctr:D0.87; 95%CI,D0.46 -D1.26; P[
.009). EuroQol 5D improved in the treatment group (Spa:D0.01; 95% CI,L0.02 -D0.04) while it worsened (Ctr:L0.07;
95% CI,L0.10 -L0.04) in the control group (P < .001). A similar pattern was found for the Chronic Venous Insufﬁciency
Questionnaire 2 scale (Spa:L2.0; 95% CI,L4.4 -D0.4; Ctr:D2.4; 95% CI,D0.2 -D4.7; P[ .008). The control patients
showed similar improvements in clinical severity, symptoms, and quality of life after their own spa treatment (day 547).
Conclusions: In this study, the incidence of leg ulcers was not reduced after a 3-week spa therapy course. Nevertheless, our
study demonstrates that spa therapy provides a signiﬁcant and substantial improvement in clinical status, symptoms, and
quality of life of patients with advanced venous insufﬁciency for at least 1 year. (J Vasc Surg 2014;59:447-54.)2In spite of the extensive development of efﬁcient
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remains a burden for both national health care systems3,4
and for patients.5 The documented impact of venoactive
drugs is limited to an improvement of symptoms.6 Most
patients have to wear compression stockings, but poor
compliance to this treatment shows in itself that it is not
the perfect answer to their expectations.7 In this context,
any adjunctive treatment able to improve the function
and quality of life of the patients is welcome.
Although scarcely evaluated for this condition, rehabil-
itation and physical therapy aimed at a restoration of calf
muscle pump function offer potentially useful adjunctive
treatments,8 and several randomized studies have shown
promising hemodynamic results.9-12
Spa treatment is a popular way to administer physical
therapy for CVDs in Europe.13-15 In France, where more
than 40,000 patients are treated annually, it is delivered
as a 3-week course of intensive balneotherapy in a spa
resort specialized in the treatment of CVD patients;
most often associated with a patient education program16
and is partly reimbursed by French national health
insurance.15447
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we observed that such spa treatment, performed in the spa
resort of La Léchère, was able to improve signiﬁcantly skin
trophic changes in patients with advanced chronic venous
insufﬁciency (CEAP C4-C5), as well as their CVD-
related quality of life and symptoms, for at least 1 year.
A trend toward a reduction in the incidence of leg ulcers
was also observed, but the numbers were too small to
reach statistical signiﬁcance. The aim of the present study
was to conﬁrm the efﬁcacy of spa treatment on the physical
status, symptoms, and quality of life in patients with
advanced chronic venous insufﬁciency (CEAP C4-C5), in
a large-scale multicenter trial, involving the 12 French
spa resorts specializing in the treatment of CVD, and in
particular, to evaluate its impact on the incidence of venous
ulcers.METHODS
Study design and organization. This was a single-
blind (treatment concealed to the investigators) random-
ized controlled trial with two parallel groups. Patients
attended a spa treatment course in addition to continuing
their usual medical care. The tested hypotheses were that
patients with advanced chronic venous insufﬁciency
(CVD with CEAP C classes C4-C5) would have
a decreased 1-year incidence of leg ulcers (primary
outcome criterion) and a long-standing improvement
(remaining signiﬁcant at month 12) in their signs, symp-
toms, and quality of life (secondary outcome criteria)
compared with a control group with no spa treatment.
Subjects. Inclusion criteria were primary or post-
thrombotic CVD with skin changes but no active ulcer
(C4a, C4b, or C5) and evidence of venous incompetence
demonstrated by duplex ultrasound examination with at least
one signiﬁcant reﬂux (of more than 1-second duration in
a standing position) in the superﬁcial, deep and/or perfo-
rator veins. Patients had to be at least 18 years old andwilling
to participate (written informed consent) in the study (ie, to
attend a 3-week course of spa treatment in one of the 12
French spa resorts treating patients with CVD) (ie, Argeles-
Gazost, Barbotan-les-Thermes, Bagnoles de l’Orne, Dax,
Evaux-les-Bains, Jonzac, La Léchère-les-Bains, Luxeuil,
Luz-Saint-Sauveur, Rochefort-sur-Mer, Saint Paul-les-Dax,
and Saubusse) and to accept a follow-up of 18 months’
duration including a monthly self-administered question-
naire and a medical examination every 6 months.
Patients were not included if a surgical or endovascular
treatment of the venous disease was planned at any time
during the entire study period (18 months) or had been
performed less than 6 months prior to the inclusion visit.
Patients with spa treatment in the previous 6 months or
a contraindication to spa treatment (life-threatening
disease, cardiac or renal failure, immunodeﬁciency, psychi-
atric disorders, severe difﬁculty walking) were also not
included, as well as those with edema of nonvenous origin
(clinical lymphedema, cardiac failure, hypoalbuminemia),
symptomatic neurologic diseases of the lower limbs(neurogenic pain or abnormal neurologic examination of
the lower limbs) or signiﬁcant peripheral arterial disease
(ankle brachial index <0.70).
Randomization. Centralized randomization was per-
formed immediately after the inclusion visit, and its result
was kept hidden from the investigator, with a stratiﬁcation
by center and CEAP C class (C4 vs C5) to ensure better
comparability. The treatment took place in the spa resort
closest to the patient’s home.
Intervention. Patients in the treatment group
attended a 3-week spa treatment course in the spa resort
closest to their home, soon after randomization. The
control group also attended a spa treatment course, but
after the comparison period (ie, starting soon after day 365;
Fig 1).
The spa treatment course was performed according to
the rules of the French health authority, and study patients
were cared for in the same way as any other CVD patient,
with their participation in the study concealed from resort
staff. The treatment regimen consisted of four balneother-
apy sessions per day, 6 days a week during 3 weeks, and
educational activities that were differently organized in
each resort. The balneotherapy sessions included15 a 15-
minute walking session in a specially designed pool with
tracks in semideep (80 cm) cool (28C) water (training
of muscle pump function under water compression);
a 20-minute whirlpool bath session with automatic air
and water massage cycles (aimed at relaxation and mobili-
zation of the superﬁcial skin volume ﬂow); a 10-minute
bath session with customized underwater strong massaging
jets (mobilization and softening of the sclerotic subcuta-
neous tissues); and a 10-minute massage session of the
leg and ankle skin areas by a registered physiotherapist
under a light spray shower (softening of the sclerotic
subcutaneous tissues) or a 15-minute joint mobilization
session in a deep (150 cm) warm (34C) pool under the
supervision of a physiotherapist (improvement of ankle,
and also knee and hip joint mobility for better ambulation
and muscle-pump functioning).
Sessions were customized for each patient by the
specialist spa physician according to the patient’s needs
and capabilities on arrival at the spa resort and at the
two medical visits systematically performed during the spa
treatment course as required by French health authority
rules.
Concomitant treatments. During the entire study
period, patients in both groups remained in the care of
their regular physician, who provided them with any treat-
ment they considered necessary, including wearing
compression stockings. No standardized basal treatment
or counseling was provided by the investigators.
Main outcome measurements. The follow-up exam-
inations were performed by the same investigator for
a given patient every 6 months during the study period,
with a ﬁnal visit at month 18. Before each visit, the patient
was reminded by the research assistant that he had to
conceal his status regarding the spa treatment from the
investigator, to maintain blinding for the evaluation.
Fig 1. Pseudo cross-over design of the study. The comparison concerns the ﬁrst year (ie, 1 year after treatment for the
treatment group, vs 1 year after randomization but before spa treatment for the control group). CIVIQ2, Chronic
Venous Insufﬁciency Questionnaire 2; EQ5D, EuroQol 5D; VCSS, Venous Clinical Severity Score.
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dence of leg ulcer, deﬁned as a wound to the lower leg
involving the dermis, which did not heal within 6 weeks
if it was the ﬁrst in a given skin area, or within 2 weeks
for a relapse at the site of a previous ulcer. Photos of the
wounds were systematically collected by the investigators,
and a critical event committee, consisting of two experi-
enced vascular physicians blinded to any treatment infor-
mation, validated the diagnosis.
Secondary outcomes. The severity of the venous
disease was evaluated using the Venous Clinical Severity
Score (VCSS), described by Rutherford et al18 modiﬁed
as follows. Spa treatment is a composite treatment that
includes patient education, with compliance to compres-
sion therapy as one of its aims; the latter was not taken into
account in the score calculation but only the parameters
related to clinical status, resulting in a modiﬁed VCSS
ranging from 0 to 27. The score was calculated for both
legs and the highest recorded.
Self-evaluation of the intensity of leg symptoms was
performed each month by the patient and reported in
a diary using two 10-cm visual analog scale (VAS). The
intensity of symptoms was rated separately for each leg,
from “no discomfort” at the bottom (0.0), to “unbear-
able” at the top (10.0), according to a method previously
described and discussed in detail.19 The ﬁrst measurement,
taken as baseline, was at month 1; for the analysis, only the
VAS of the most severely affected leg was taken into
account.
Quality of life was measured every 6 months by the
validated French versions of the generic EuroQol 5D
instrument20 and the vein-speciﬁc self-administered
Chronic Venous Insufﬁciency Questionnaire 2 (CIVIQ2),
a disease-speciﬁc quality-of-life instrument dedicated to
CVDs and validated in French for this condition.21 Inaddition to the overall CIVIQ2 scale, its four components
(pain, physical, psychological, and social components) were
separately analyzed.
Data regarding the direct cost of medical and nursing
care were recorded for subsequent medicoeconomic anal-
ysis, but are not reported in this article.
At each visit, any adverse events were recorded and any
change in the patient’s treatment. The diagnosis of erysip-
elas22 and venous thromboembolic events were blindly
evaluated by the critical event committee in the same way
as for the leg ulcers.
All data (including images) were recorded using an
electronic case report form with automated controls (Clin-
info) to minimize data capture errors and to allow imme-
diate quality control.
Data management and statistical analysis. Study
coordination, monitoring visits to each center, data
management, data entry from patient questionnaires, and
data analysis were performed by the Grenoble Clinical
Research Center. Data managers were blinded to the
randomization, including for the ﬁnal data review
regarding protocol deviations and missing data.
The main outcome analysis was conducted as intention
to treat. The primary and secondary outcome criteria were
assessed at 12 months. The ﬁnal examination at month 18
was analyzed as a supplementary evaluation of the early
effects of spa treatment in the control group.
The statistical analyses were performed with Stata (v. 12;
StataCorp, College Station, Tex). Qualitative variables are
presented as the number and percentages and continuous
variables by the mean and 95% conﬁdence interval. A c2
test was performed for categorical data such as the incidence
of leg ulcers and Fisher exact test if necessary. For quantita-
tive variables, Student t-tests were performed on the differ-
ences M12-M0 (and M6-M0).
Fig 2. Study ﬂow chart. CVDs, Chronic venous disorders.
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from the expected reduction in the incidence of leg ulcers,
which required more patients than the other end points.
Our hypothesis was based on a yearly incidence of 20% in
the control group compared with 10% in the treated group,
with an alpha risk of 5% and a power of 80%. One hundred
ninety-nine subjects were needed for the comparison, and
we decided to include 440 patients to allow for dropouts.
The study protocol was approved by the regional ethics
committee institutional review board 11263 (Comité de
Protection des Personnes Sud-Est II) on April 11, 2008
and the French regulatory authorities (ANSM) Eudract
N 2008-A00197-48. It was registered on http://www.
clinicaltrials.gov: NCT00838500.RESULTS
Description of the subjects and interventions. The
study ﬂow chart is shown in Fig 2. Out of the 780
patients screened for inclusion, most (746) were in
response to advertisements in the regional press, and 355
of these were found to be ineligible mainly because they
did not show C4 or C5 CVD (n ¼ 271); were not available
for a spa treatment (n ¼ 35); refused (n ¼ 7); had
a contraindication to spa treatment (n ¼ 10); had an open
(n ¼ 8) or a recent leg ulcer (n ¼ 5); had peripheral arterial
disease, peripheral neuropathy, or recent erysipelas (n ¼
11); or had a recent (n ¼ 6) or planned (n ¼ 19) venous
intervention or had recent spa treatment (n ¼ 2).
The comparison of randomized subjects is shown in
Table I. Similar distributions of demographic and prog-
nostic as well as baseline criteria were found in both
groups.Nine patients in the “spa treatment” group did not
attend their spa course; nevertheless, they are included in
the analysis (intention-to-treat approach). The delay
between randomization and spa therapy ranged from 3
to 74 days (median, 24 days). The most frequently
attended spa therapy sessions were the whirlpool bath
(88%), the in-water walking sessions (81%), the underwater
massage (79%), and the light shower massage (28%). Sixty-
six percent attended a therapeutic education program.
Appendix I (online only) gives further details of the spa
treatments.
Forty-six patients from the control group did not
attend the spa treatment course, whereas 29 subjects
from the treated group attended a second spa course at
their own initiative (nine before the end of the ﬁrst year),
because they thought they had beneﬁted from this treat-
ment and did not want to wait for 2 years (due to the
seasonal activity of the spa resorts) before repeating it.
These deviations had little effect on the outcome criteria,
since they mostly occurred after the planned 12-month
comparison period; however, they could substantially inﬂu-
ence the observations during the poststudy follow-up
(months, 13-18).
Incidence of leg ulcers. No difference regarding the
1-year incidence of leg ulcers was found between the
groups, or between their C4 and C5 subgroups (Table II).
The physical state of veins, as measured by the modi-
ﬁed VCSS, was found to be signiﬁcantly improved after
1 year in the spa treatment group (Spa: 1.2; 95% conﬁ-
dence interval [CI], 1.6 - 0.8) compared to controls
(Ctr: 0.6; 95% CI, 1.0 - 0.2; P ¼ .040; Fig 3).
Leg symptoms, as assessed by monthly self-evaluation
using the VAS, were considerably improved, with a maximal
Table II. Incidence of leg ulcers at 1 year in both groups,
and in the C4 and C5 subgroups
Incidence of leg
ulcers at 1 year
Controls,
No. (%) [95% CI]
Spa treatment,
No. (%) [95% CI] P
Total population (n ¼ 197) (n ¼ 193) .231
Ulcers 12 (6.1) 18 (9.3)
[3.2-10.4] [5.6-14.3]
C4 subgroup (n ¼ 120) (n ¼ 115) 1.0
Ulcers 3 (2.5) 3 (2.6)
[0.5-7.1] [0.5-7.4]
C5 subgroup (n ¼ 77) (n ¼ 78) .194
Ulcers 9 (11.7) 15 (19.2)
[5.5-21.0] [11.2-29.7]
CI, Conﬁdence interval.
Fig 3. Time course of variations in the Venous Clinical Severity
Score (modiﬁed VCSS) (mean6 standard error of the mean) (solid
lines ¼ comparative period; dotted lines ¼ follow-up) At *: P < .05
for the difference with M0. At the end of 1 year, the improvement
in VCSS was signiﬁcantly greater in treated patients than in
controls. After 1 year, the control patients were given the spa
treatment and their VCSS scores caught up with those of the other
group.
Fig 4. Time course of variations in leg symptoms as assessed by
monthly visual analog scale (VAS) (mean 6 standard error of the
mean) (solid lines ¼ comparative period; dotted lines ¼ follow-up).
At **: P < .01 for the difference with M0. After spa therapy, the
treated group soon experienced a reduction in leg symptoms,
which reached a maximum at 4 to 6 months. The difference with
the control group remained substantial and highly signiﬁcant for
the entire year. After month 12 and their own spa treatment, the
control patients also showed a dramatic improvement in their
symptoms.
Table I. Baseline characteristics of patients
Characteristics
Controls
(n ¼ 211)
Spa treatment
(n ¼ 214)
Male 94 (45) 92 (43)
Age 65.1 (9.2) 63.5 (9.4)
BMI 29.6 (6.1) 30.1 (6.2)
Sequelae of DVT
(duplex ultrasound)
105 (50) 100 (47)
Previous spa therapy 45 (21) 37 (17)
Venous incompetence
(duplex ultrasound)
Superﬁcial 173 (82) 181a (85)
Perforator 142 (67) 148 (69)
Deep 103 (49) 97 (45)
CEAP “C” classiﬁcation
C4a 95 (45) 82 (38)
C4b 35 (17) 45 (21)
C5 81 (38) 87 (41)
Treatment (at the time of inclusion)
Anticoagulant therapy 25 (12) 28 (13)
Venoactive drug 69 (33) 72 (34)
Compression therapy 157 (74) 165 (77)
Level of compression: strength 1-2 136 (89) 135 (85)
Strength 3 15 (9.8) 23 (15)
Strength 4 (strongest) 2 (1.3) 1 (0.6)
Physiotherapy 8 (4) 8 (4)
Outcome criteria
Modiﬁed VCSS 8.2 (3.0) 8.6 (3.1)a
EQ5D 0.75 (0.22)b 0.72 (0.21)b
CIVIQ2 36.5 (19.9) 38.4 (20.2)a
VASc 4.83 (2.79) 4.62 (3.05)
BMI, Body mass index; CIVIQ2, Chronic Venous Insufﬁciency Question-
naire 2; DVT, deep vein thrombosis; EQ5D, EuroQol 5D; SD, standard
deviation; VAS, visual analog scale.
Continuous data are presented as mean 6 standard deviation and categoric
data as number (%).
aOne missing value.
bFive missing values.
cVAS at month M1, n ¼ 151 controls and 143 spa.
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95% CI, 1.36 - 0.40; Ctr: M6-M1 ¼ þ0.14; 95% CI,
0.16 - þ0.44; P < .001) and remained signiﬁcantly
improved 1 year after treatment (Spa: M12-M1 ¼ 0.03;
95% CI, 0.57 - þ0.51; Ctr: M12-M1 ¼ þ0.87; 95% CI,
þ0.46 - þ1.26; P ¼ .009; Fig 4).Vein-related quality of life, as expressed by the CIVIQ2
scale, for which the score decreases when quality of life
improves, also improved signiﬁcantly at 6 months (Spa:
M6-M0 ¼ 4.77; 95% CI, 6.88 - 2.66; Ctr: M6-
M0 ¼ 0.09; 95% CI, 2.17 - þ1.99; P ¼ .002) and
remained signiﬁcantly improved at 12 months (Spa:
M12-M0 ¼ 2.0; 95% CI, 4.4 - þ0.4; Ctr: M12-
M0 ¼ þ2.4; 95% CI, þ0.2 - þ4.7; P ¼ .008; Fig 5). All
four components of the CIVIQ2 scale showed similar
Fig 5. Time course of variations in the venous-related quality-of-
life scale Chronic Venous Insufﬁciency Questionnaire 2 [CIVIQ2]
(mean 6 standard error of the mean). Higher scores are related to
larger changes in quality of life (solid lines ¼ comparative period;
dotted lines ¼ follow-up). At **: P < .01 for the difference with
M0. In spite of seasonal variations (the spa treatment is performed
mostly during summer months), the treated group showed
a substantial and signiﬁcant improvement vs the control group,
with the difference remaining signiﬁcant at month 12. Again, after
the control patients were given spa treatment, their CIVIQ2 scale
reached the same level as the other group.
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showed signiﬁcant differences at month 12 (Fig 6).
General health-related quality of life, as measured by
the EuroQol 5D scale also showed a similar difference at
month 6 (Spa: M6-M0 ¼ þ0.01; 95% CI, 0.02 - þ0.05;
Ctr: M6-M0 ¼ 0.05; 95% CI, 0.09 - 0.02; P ¼ .003),
remaining signiﬁcant after 1 year (Spa: M12-M0 ¼ þ0.01;
95% CI, 0.02 - þ0.04; Ctr: M12-M0 ¼ 0.07; 95% CI,
0.10 - 0.04; P < .001; Fig 7).
The control group responded in a similar manner to
the treatment group to its own postponed spa treatment
course (immediately after month 12), with approximately
the same magnitude of improvement at month 18 as in
the treatment group at month 6, for physical status, symp-
toms, and quality of life (Figs 3-7).
Compression stockings were used by 76% of patients in
both groups as part of their “usual treatment” (see Table I
and Appendix II, online only, for details of use during
follow-up).
Tolerance. Forty-seven serious adverse events were re-
ported during this 18-month study in the 425 patients, 26
in the control group and 21 in the treatment group. Most
(44) were unexpected hospitalizations for various reasons
unrelated to the spa treatment according to the investi-
gator. Only ﬁve types of severe adverse events (erysipelas,
inﬂammatory lesions, reopening of old ulcer, ulcer recur-
rence, varicose vein surgery) were possibly or probably
ascribed to the spa treatment according to the investiga-
tors. One subject in the control group died from esopha-
geal cancer with metastasis.
Particular attention was paid to erysipelas and throm-
boembolic events in this population. Nine cases oferysipelas were reported, seven in the treatment group
and two in the control group: 5 occurring before or at least
6 months after the spa treatment, 1 occurred during the 3-
week spa course, and 3 within 1 month after the end of the
spa course. Thirteen patients experienced a thromboem-
bolic event, three in the treatment group and 10 in the
control group; most of these events, however, were minor:
eight cases of superﬁcial thrombophlebitis, four of distal
deep vein thrombosis, and only one clinical pulmonary
embolism (in the control group).
DISCUSSION
We found spa treatment to have no effect on the inci-
dence of leg ulcers. Several factors may explain this. (1)
The annual incidence of leg ulcers in the control group
(6.1%) was more than three times lower than expected
(20%, ie, 30% in C5 and 10% in C4 patients) from the liter-
ature,23 and this considerably reduced the power of the
study for the primary outcome. (2) The patients enrolled
in this study showed good compliance to compression
therapy (76%) meeting one of the aims of the American
Venous Forum program on the prevention of venous ulcers
(75% compliance within 5 years).24 Good compliance
could explain both the low incidence of ulcers and the difﬁ-
culty to demonstrate any additional therapeutic beneﬁt on
top of such well-conducted “usual treatment.” (3) Spa
treatment is a multifaceted health intervention whose
educational component may help prevent leg ulcers by
improving compliance to usual therapies such as compres-
sion therapy. Nevertheless, in this study, spa treatment as
currently practiced in France provided no improvement
in the incidence of leg ulcers per se at 1 year.
However, for the secondary criteria this large-scale
multicenter randomized controlled trial conﬁrms our
previous ﬁnding in a single-center trial that spa therapy is
beneﬁcial as adjunctive treatment to the usual medical
care of patients with severe CVD. Our results clearly
show a signiﬁcant improvement in the CVD-related phys-
ical status (VCSS), symptoms (VAS), and quality of life
(CIVIQ2 and EuroQoL 5D scales). These effects are sus-
tained for at least 1 year.
This trial was not double-blinded. This may be feasible
for a comparison of the effects of different mineral waters
or for assessing a technical parameter of balneotherapy, but
not for evaluating the overall effect of the spa treatment
course, which was our aim. Nevertheless, we made all
possible efforts to avoid any evaluation bias, with centralized
randomization bypassing the investigator, and blinded data
management, critical event evaluation and statistical analysis.
The unusual design of the study (Fig 1), with a spa
treatment given to the control group following the 1-
year comparison period, was adapted from studies of spa
therapy for severe low back pain.25 In our previous smaller
study,17 we had found that this approach avoided dropouts
in the control group, and we are, thus, able to reasonably
rule out a disappointment bias in the control group. The
treatment tested was the course of spa therapy taken as
a whole, as deﬁned and reimbursed by French health
Fig 6. Time course of variations in the four components of the Chronic Venous Insufﬁciency Questionnaire 2
(CIVIQ2) scale (solid lines ¼ comparative period; dotted lines ¼ follow-up). At *: P < .05; and at **: P < .01 for the
differences with M0. All four subscales of the CIVIQ2 quality-of-life instrument, related to psychological (A), physical
(B), pain (C), and social (D) components, were signiﬁcantly improved in the treated group compared to the controls,
with similar time course patterns.
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nent of the therapy and their potential synergy but do not
allow us to differentiate between the effects of each compo-
nent, including the possible effects of the nature of the
mineral water,26 the therapeutic education,16 and the
psycho-sociological inﬂuence of a 3-week health-centered
retreat, as well as the intensive active balneotherapy.
In the absences of contraindications,15 tolerance was very
good. Thus, a spa treatment course could be proposed to all
patients with advanced chronic venous insufﬁciencies who
are able to invest their time in it, particularly in cases with
post-thrombotic syndrome, when the restoration of satisfac-
tory hemodynamic venous functionmaybedifﬁcult to achieve.
CONCLUSIONS
This study conﬁrms our previous smaller monocenter
randomized controlled trial. It shows that a spa therapy
course, adapted to the treatment of patients with CVD,
although not reducing the incidence of leg ulcers, signiﬁ-
cantly improves their CVD-related physical status, symp-
toms, and quality of life when used as an adjunct to usual
medical care. These effects are large and remain signiﬁcant1 year after the spa therapy, justifying its use in patients
with advanced chronic venous insufﬁciency who do not
have the possibility of surgical or endovascular treatments.
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Fig 7. Time course of variations in the generic quality-of-life index
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Details of spa therapy
(spa treatment group only)
d In the spa treatment group, 205 patients attended the
spa therapy course. The spa treatment physician ﬁlled in the
spa treatment case report form for 198 patients.
The spa treatment includedType of treatment
Spa treatment group
(n ¼ 198)
Whirlpool bath with automatic air and
water massage
175 (88%)
Number of sessions, median [IQR] 18 [18-18] (n ¼ 174)
Controlled walking in semideep water 160 (81%)
Number of sessions, median [IQR] 18 [18-18] (n ¼ 160)
Bath with underwater strong
massaging jets
156 (79%)
Number of sessions, median [IQR] 18 [18-18] (n ¼ 156)
Massage by physiotherapist under a light
spray shower
56 (28%)
Number of sessions, median [IQR] 9 [9-18] (n ¼ 56)
Simple bath 32 (16%)
Number of sessions, median [IQR] 18 [18-18] (n ¼ 32)
Massage underwater by physiotherapist 11 (6%)
Number of sessions, median [IQR] 18 [9-18] (n ¼ 11)
Application of thermal mud 11 (6%)
Number of sessions, median [IQR] 18 [18-18] (n ¼ 11)
Gymnastics in deep water 10 (5%)
Number of sessions, median [IQR] 9 [8-9] (n ¼ 10)
Other treatments 151 (76%) (n ¼ 198)
IQR, Interquartile range.APPENDIX II (online only).
Use of compression stockings
Compliance was considered as positive if the frequency
of use of compression stockings increased or remained the
same when used nearly daily or daily.
Among the 425 patients analyzed, n ¼ 261 patients
had compression therapy that had been prescribed by their
usual physician at inclusion and at 6 months. Of these,
information on their compliance is available at both inclu-
sion and 6 months for n ¼ 238 patients.
Among the 425 patients analyzed, n ¼ 232 patients
had compression therapy that had been prescribed by their
usual physician at inclusion and at 12 months. Of these,
information on their compliance is available at both inclu-
sion and 12 months for n ¼ 217 patients.Inclusion Controls Spa treatment
Compression therapy 157/211 (74.4%) 165/214 (77.1%)
If yes, strength
1-2 136/153 (88.9%) 135/159 (84.9%)
3 15/153 (9.8%) 23/159 (14.5%)
4 (strongest) 2/153 (1.3%) 1/159 (0.6%)
If yes, compliance
Not compliant 7/152 (4.6%) 7/150 (4.7%)
Intermittent 59/152 (38.8%) 63/150 (42.0%)
Nearly daily 35/152 (23.0%) 32/150 (21.3%)
Daily 51/152 (33.6%) 48/150 (32.0%)
Controls Spa treatment P
6 months
Compression therapy 157/193 (81.3%) 150/190 (78.9%) .556
If yes, compliance .526
Not compliant 7/150 (4.7%) 3/142 (2.1%)
Intermittent 46/150 (30.7%) 38/142 (26.8%)
Nearly daily 33/150 (22.0%) 33/142 (23.2%)
Daily 64/150 (42.7%) 68/142 (47.9%)
12 months
Compression therapy 131/184 (71.2%) 142/185 (76.8%) .223
If yes, compliance .627
Not compliant 7/128 (5.5%) 4/139 (2.9%)
Intermittent 39/128 (30.5%) 45/139 (32.4%)
Nearly daily 30/128 (23.4%) 28/139 (20.1%)
Daily 52/128 (40.6%) 62/139 (44.6%)
